secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEAYA Biosciences, Inc. (IDYA)
CIK:        0001676725
Form:       8-K
Filed at:   2023-05-16T23:59:59+00:00
Accession:  0000950170-23-022333
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IDEAYA expands Pfizer collaboration to support Phase 2/3 registrational trial for darovasertib + crizotinib in 1L MUM
--------------------------------------------------------------------------------

- Amendment increases crizotinib supply for planned Phase 2/3 trial evaluating darovasertib + crizotinib in first-line HLA-A2 negative MUM.
- Pfizer to provide first defined quantity at no cost; additional second quantity at lump-sum cost to IDEAYA.
- Termination of prior Pfizer agreement for Phase 1 trial in cMET-driven tumors (NSCLC/HCC).
- Trial initiation targeted for Q2 2023; PFS primary endpoint for potential accelerated approval.
- IDEAYA owns commercial rights to darovasertib subject to Novartis license obligations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1676725/000095017023022333/0000950170-23-022333-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1676725/000095017023022333/idya-20230512.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-022333

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer